Occupation: Research House
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants.
Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries.
Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).
Run by a team of highly experienced professionals, our aim is to provide the research of choice for companies, investment banks and institutional investors. We provide independent reports, forecasts and valuations on each company we cover. We help clients gain access to investors, and facilitate feedback from the investment community on companies, their management and strategies. Our research strives to be objective, insightful, financially rigorous, readable and timely.
Web Address: http://www.edisongroup.com
280 High Holborn
Tel: Tel: +44 (0)20 3077 5700
International Biotechnology Trust (IBT) provides investors with exposure to the fast-growing biotechnology market through both quoted (86%) and unquoted investments (14%). Secular drivers, include ageing populations, increasing demand in emerging markets and acceleration in new product development, are encouraging. Sector valuations have expanded but, in the manager's view, are still reasonable with median large-cap biotech estimated PEG ratio standing at c 1.2x.
Long-term investment in digital technology has supported growth in recent years, despite challenged market conditions in the group's main distribution channels (UK small and mid-sized businesses and consumers) and depressed interest earnings on its substantial cash balances. Product innovation continues, with the flexecash prepaid card at the vanguard. Weakness in the demand from one group of customers in the home collected credit sector has caused…
Vectura's partner Sandoz has received its first European approval in Denmark for AirFluSal, a generic version of GSK's Seretide for asthma/chronic obstructive pulmonary disease (COPD). AirFluSal, formerly VR315, is delivered via Vectura's proprietary Gyrohaler inhaler. It is the third Vectura-developed respiratory product to receive European approval following those of the two Novartis-partnered COPD drugs, Seebri Breezhaler (in 2012) and Ultibro Breezhaler (earlier in 2013). Royalties…
Smiths' site visit to one of its John Crane super service centres in Dubai allowed us to better appreciate the business model, meet management and hear how the targeted 4-6% organic growth will be achieved. We believe this could well be conservative given John Crane's market share, the high proportion of aftermarket services (two-thirds of JC revenue) and sticky return business (>90%). This will be…
In 2013 Cooks Global Foods (CGF) has transformed from a small listed shell company to the owner of a global franchise cafe business, Esquires Coffee. This has been achieved via the acquisition for shares of a number of businesses, which gives the company a platform of 57 stores in the UK, Ireland, China and the Middle East. CGF is now working on growing this to…